I haven't sold any but am down considerably. I think lots of margin accounts got hit on this one. Especially since initially the news wasn't so bad last Friday when ABBV's pricing came out and we saw no reprucussions and went through the weekend feeling pretty confident. Then Monday morning the news of Express Script signing an exclusive with ABBV hit the wires and a lof of us got caught off-guard. Was one stinky smelling Xmas present!
On a daily chart, there appears to be a support level of $104. At the moment, any dips could present an attractive opportunity to go long. There is a consensus forecast 12-month target of $120.40, according to a Bloomberg poll. There are 34 buy calls, three recommendations to hold and two sell calls.
This from IMS: Evercore Partners said that weekly prescriptions of the firm's Hepatitis C drugs Harvoni and Sovaldi totaled 9,412 this week, increasing 3.4% from last week. Harvoni TRx totaled 6,515, up 6.7% from last week and Sovaldi TRx totaled 2,896, down 3.2% from last week.
The broker also noted that Sovaldi and Harvoni IMS scripts need to average around 6,500 in Q4 to meet the current domestic sales estimate of $2.75 billion. Currently, the average is 7,081 scripts.
Rather 5 bil over next 2 months and a new 5 - 10 bil over the next 12. Sorry
...09:55 AM EST, 12/26/2014 (MT Newswires) -- Gilead Sciences ( GILD ) shares climbed Friday morning after RBC Capital said the biopharmaceutical firm could launch a new share buyback program of $5 billion to $10 billion over the next year after finishing its current $5 billion buyback plan over the next couple of months.
The broker said a new $5 billion to $10 billion share buyback would "make easy financial sense," as it would be a smart way to use "billions of cash building up right now," and provide "confidence to the market that there are no fundamental changes to the outlook," Seeking Alpha reported.
RBC Capital noted how GILD shares fell recently following news that Express Scripts ( ESRX ) sealed an exclusive HCV deal with AbbVie ( ABBV ) . The broker said the agreement will only impact approximately 2% to 10% of the HCV market, and that GILD stock will ultimately recover.
GILD shares were up 2.7% at $93.77 in recent morning trading, within a 52-week range of $63.50 to $116.83.
Price: 93.78, Change: +2.49, Percent Change: +2.73
I totally disagree with Cramer on this latest call! GILD's product is far superior to that of ABBV's and who the hell wants to have to swallow that many pills? Americans want the best and are willing to pay for the best!
Everyone should ask their doctor not to send the script to Express Scripts and fill it elsewhere. Its crazy that we have to go to another country now in order to get the medication we need! This is plum nuts!!!
BIIB is down over $16. Whole sector is down.
It is time for GILD management to step up to the plate however and turn lemons into lemonade. This could be an opportunity if they play the cards right.